Search research articles
Contact Us
Filters
Showing results (161-170 of 743) with videos related to
Page
of 75
Sort By:
Acta Medica Austriaca
|
January 1, 1989
Novel approaches to intraperitoneal drug delivery
S B Howell, S Kirmani, R Goel
European Journal of Cancer & Clinical Oncology
|
September 1, 1985
Nephrotoxicity of high-dose intracavitary cisplatin with intravenous thiosulfate protection
M Markman, S Cleary, S B Howell
Blood
|
March 1, 1980
Thymidine as a chemotherapeutic agent: sensitivity of normal human marrow, peripheral blood T cells, and acute nonlymphocytic leukemia
S B Howell, R Taetle, J Mendelsohn
Journal of Cellular Physiology
|
June 1, 1994
Cisplatin sensitivity correlates with its ability to cause cell cycle arrest via a wee1 kinase-dependent pathway in Schizosaccharomyces pombe
F Thiebaut, R Enns, S B Howell
Cancer Research
|
April 1, 1979
Cytokinetic comparison of thymidine and leucovorin rescue of marrow in humans after exposure to high-dose methotrexate
S B Howell, A Krishan, E Frei
Molecular Biology & Medicine
|
October 1, 1987
Evidence against ras activation in human ovarian carcinomas
M Haas, J Isakov, S B Howell
Cancer Chemotherapy and Pharmacology
|
January 1, 1989
Pharmacologic basis for the use of dipyridamole to increase the selectivity of intraperitoneally delivered methotrexate
R Goel, R Sanga, S B Howell
Molecular Pharmacology
|
November 1, 1996
Isolation and characterization of a cisplatin-resistant strain of Schizosaccharomyces pombe
P Perego, G Jimenez, S B Howell
Cell Communication and Signaling : CCS
|
October 26, 2014
Claudin-4 controls the receptor tyrosine kinase EphA2 pro-oncogenic switch through β-catenin
Xiying Shang, Xinjian Lin, Stephen B Howell
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 1, 1997
Pharmacological basis for a novel therapeutic strategy based on the use of aquated cisplatin
H Zheng, D Fink, S B Howell
Page
of 75
Search research articles
Search
Showing results (161-170 of 743) with videos related to
Sort By:
Page
of 75
Acta Medica Austriaca
|
January 1, 1989
Novel approaches to intraperitoneal drug delivery
S B Howell, S Kirmani, R Goel
European Journal of Cancer & Clinical Oncology
|
September 1, 1985
Nephrotoxicity of high-dose intracavitary cisplatin with intravenous thiosulfate protection
M Markman, S Cleary, S B Howell
Blood
|
March 1, 1980
Thymidine as a chemotherapeutic agent: sensitivity of normal human marrow, peripheral blood T cells, and acute nonlymphocytic leukemia
S B Howell, R Taetle, J Mendelsohn
Journal of Cellular Physiology
|
June 1, 1994
Cisplatin sensitivity correlates with its ability to cause cell cycle arrest via a wee1 kinase-dependent pathway in Schizosaccharomyces pombe
F Thiebaut, R Enns, S B Howell
Cancer Research
|
April 1, 1979
Cytokinetic comparison of thymidine and leucovorin rescue of marrow in humans after exposure to high-dose methotrexate
S B Howell, A Krishan, E Frei
Molecular Biology & Medicine
|
October 1, 1987
Evidence against ras activation in human ovarian carcinomas
M Haas, J Isakov, S B Howell
Cancer Chemotherapy and Pharmacology
|
January 1, 1989
Pharmacologic basis for the use of dipyridamole to increase the selectivity of intraperitoneally delivered methotrexate
R Goel, R Sanga, S B Howell
Molecular Pharmacology
|
November 1, 1996
Isolation and characterization of a cisplatin-resistant strain of Schizosaccharomyces pombe
P Perego, G Jimenez, S B Howell
Cell Communication and Signaling : CCS
|
October 26, 2014
Claudin-4 controls the receptor tyrosine kinase EphA2 pro-oncogenic switch through β-catenin
Xiying Shang, Xinjian Lin, Stephen B Howell
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 1, 1997
Pharmacological basis for a novel therapeutic strategy based on the use of aquated cisplatin
H Zheng, D Fink, S B Howell
Page
of 75